Skin Abnormalities: Clinical Trials

21 trials for Skin Abnormalities, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

21 terminated. 21 Phase 2, 7 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 221Terminated 21
Phase 17Terminated 7
Phase 32Terminated 2

Follow Skin Abnormalities: new trials by email Literature Review of Skin Abnormalities trials Research Report on Skin Abnormalities

Trials (filtered) newest first · largest first

All 21 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 Deficiency
INZ-701 - Gene Mutations, Pseudoxanthoma Elasticum
Phase 2TerminatedInozyme Pharma222024-06-192026-10-19
A Study to Explore Safety, Pharmacokinetics, and Early Clinical Signal of Efficacy of DS-2325a in Patients With Netherton Syndrome
DS-2325a, Placebo - Netherton Syndrome
Phase 1 / Phase 2TerminatedDaiichi Sankyo92023-09-282026-05-14
A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Netherton Syndrome
Spesolimab - solution for infusion, Placebo matching to spesolimab - solution for infusion, Spesolimab - solution for injection - Netherton Syndrome
Phase 2 / Phase 3TerminatedBoehringer Ingelheim432023-06-122026-03-12
The TELO-SCOPE Study: Attenuating Telomere Attrition With Danazol. Is There Scope to Dramatically Improve Health Outcomes for Adults and Children With Pulmonary Fibrosis
Danazol, Placebo - Pulmonary Fibrosis, Telomere Shortening
Phase 2TerminatedThe University of Queensland292021-09-072025-08-05
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Participants With Ichthyosis
Imsidolimab, placebo - Ichthyosis
Phase 2TerminatedVanda Pharmaceuticals52021-01-252025-09-16
HORIZON: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
GT005 - Dry Age-related Macular Degeneration
Phase 2TerminatedGyroscope Therapeutics Limited2552020-09-282026-01-28
A Pilot Study of the Efficacy and Safety of Dupilumab Versus Placebo in Patients With Netherton Syndrome
Dupilumab Prefilled Syringe, Placebo Prefilled Syringe - Netherton Syndrome
Phase 2 / Phase 3TerminatedUniversity Hospital, Toulouse102020-07-232026-09-21
A Study of Patidegib Topical Gel, 2%, for the Reduction of Disease Burden of Persistently Developing Basal Cell Carcinomas in Patients With Non-Gorlin High Frequency BCC
Patidegib Topical Gel, 2%, Patidegib Topical Gel, Vehicle - Recurrent Basal Cell Carcinoma
Phase 2TerminatedSol-Gel Technologies, Ltd.502019-12-202026-07-21
Evaluation of the Safety and Efficacy Study of RGN-137 Topical Gel for Junctional and Dystrophic Epidermolysis Bullosa
RGN-137, Placebo - Junctional Epidermolysis Bullosa, Dystrophic Epidermolysis Bullosa
Phase 2TerminatedLenus Therapeutics, LLC42019-05-222022-08-22
A Safety, Efficacy and Systemic Exposure Study of CD5789 Cream in Adults and Adolescents With Lamellar Ichthyosis
CD5789 Cream 200 µg/g, CD5789 Cream 100 µg/g, CD5789 Cream Vehicle - Lamellar Ichthyosis
Phase 2TerminatedMayne Pharma International Pty Ltd652019-05-012023-08-14
EXPLORE: A Phase II Study to Evaluate the Safety and Efficacy of Two Doses of GT005
GT005 - Dry Age-related Macular Degeneration
Phase 2TerminatedGyroscope Therapeutics Limited982019-04-262026-01-27
FOCUS: A Phase I/II First in Human Study to Evaluate the Safety and Efficacy of GT005 Administered in Subjects With Dry AMD
GT005, GT005 / Device: Orbit™ Subretinal Delivery System - Dry Age-related Macular Degeneration, Macular Degeneration
Phase 1 / Phase 2TerminatedGyroscope Therapeutics Limited562018-12-172026-01-28
A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene
QR-313, Placebo - Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
Phase 1 / Phase 2TerminatedPhoenicis Therapeutics22018-07-022021-08-25
Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With JEB (HOLOGENE17)
Transplantation surgery of genetically corrected cultured epidermal autograft (ATMP) - Junctional Epidermolysis Bullosa
Phase 1 / Phase 2TerminatedHolostem s.r.l.12018-03-192022-03-07
Safety and Efficacy of Diacerein 1% Ointment for Subjects With Epidermolysis Bullosa Simplex (EBS)
diacerein 1% ointment, A placebo ointment - Epidermolysis Bullosa Simplex
Phase 2TerminatedCastle Creek Pharmaceuticals, LLC542017-06-012019-11-05
Clinical Trial to Assess Safety and Efficacy of Autologous Cultured Epidermal Grafts Containing Epidermal Stem Cells Genetically Modified in Patients With RDEB.
Genetically corrected cultured epidermal autograft (ATMP) - Recessive Dystrophic Epidermolysis Bullosa
Phase 1 / Phase 2TerminatedHolostem s.r.l.32017-01-302022-02-16
A Study of FCX-007 for Recessive Dystrophic Epidermolysis Bullosa (RDEB)
FCX-007 - Epidermolysis Bullosa Dystrophica, Recessive
Phase 1 / Phase 2TerminatedCastle Creek Biosciences, LLC.62016-07-012023-02-08
Open-Label Extension Study to Evaluate the Safety of SD-101 Cream in Participants With Epidermolysis Bullosa
SD-101 dermal cream (6%) - Epidermolysis Bullosa
Phase 2TerminatedScioderm, Inc.422014-03-262019-11-04
Doxorubicin vs. Trabectedin Plus Doxorubicin in Non Operable and/or Metastatic STS
Doxorubicin, Trabectedin - Sarcoma
Phase 2TerminatedGrupo Espanol de Investigacion en Sarcomas1152009-11-012015-10-27
Safety and Efficacy Trial of Danazol in Patients With Fanconi Anemia or Dyskeratosis Congenita
danazol - Fanconi Anemia, Dyskeratosis Congenita
Phase 1 / Phase 2TerminatedBoston Children's Hospital52009-11-012019-02-19

Showing 20 of 21. Sign in to see all of them.

Narrower conditions

Epidermolysis Bullosa Dystrophica (4)  ·  Anetoderma (3)  ·  Epidermolysis Bullosa (3)  ·  Eye Diseases (3)  ·  Geographic Atrophy (3)  ·  Netherton Syndrome (3)  ·  Retinal Degeneration (3)  ·  Retinal Diseases (3)  ·  Dyskeratosis Congenita (2)  ·  Epidermolysis Bullosa, Junctional (2)  ·  Arterial calcification of infancy (1)  ·  Basal Cell Nevus Syndrome (1)  ·  Carcinoma, Basal Cell (1)  ·  Epidermolysis Bullosa Simplex (1)  ·  Fanconi Anemia (1)

Broader conditions

Skin Diseases (21)  ·  Skin and Connective Tissue Diseases (21)  ·  Congenital Abnormalities (18)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (18)  ·  Genetic Diseases, Inborn (17)  ·  Skin Diseases, Genetic (17)  ·  Connective Tissue Diseases (8)  ·  Skin Diseases, Vesiculobullous (8)  ·  Infant, Newborn, Diseases (6)  ·  Keratosis (6)  ·  Epidermolysis Bullosa (5)  ·  Ichthyosis (5)  ·  Abnormalities, Multiple (4)  ·  Collagen Diseases (4)

Interventions

Danazol (2)  ·  cyclic adenosine-5'-trimetaphosphate (2)  ·  Doxorubicin (1)  ·  Injections (1)  ·  Ointments (1)  ·  Trabectedin (1)  ·  diacerein (1)  ·  spesolimab (1)  ·  thymosin beta(4) (1)  ·  trifarotene (1)

Sponsors

Gyroscope Therapeutics Limited (3)  ·  Holostem s.r.l. (2)  ·  Boehringer Ingelheim (1)  ·  Boston Children's Hospital (1)  ·  Castle Creek Biosciences, LLC. (1)  ·  Castle Creek Pharmaceuticals, LLC (1)  ·  Daiichi Sankyo (1)  ·  Grupo Espanol de Investigacion en Sarcomas (1)  ·  Inozyme Pharma (1)  ·  Lenus Therapeutics, LLC (1)  ·  Mayne Pharma International Pty Ltd (1)  ·  Phoenicis Therapeutics (1)  ·  RegeneRx Biopharmaceuticals, Inc. (1)  ·  Scioderm, Inc. (1)  ·  Sol-Gel Technologies, Ltd. (1)

Countries

United States (14)  ·  France (9)  ·  United Kingdom (7)  ·  Australia (6)  ·  Germany (6)  ·  Spain (5)  ·  Austria (3)  ·  Israel (3)  ·  Netherlands (3)  ·  Poland (2)  ·  Bulgaria (1)  ·  Canada (1)  ·  China (1)  ·  Italy (1)  ·  Japan (1)

Top investigators

Johann W. Bauer, MD (2)  ·  Michele De Luca, MD/Professor (2)  ·  Andres Poveda, Ph.M. (1)  ·  Colin A Sieff, MB.BCh (1)  ·  David R Crockford (1)  ·  Javier Martin Broto, PhM (1)  ·  Keith A. Choate, MD (1)  ·  Kurt Gunter, MD (1)  ·  Mary Spellman, MD (1)

Results publications

PMID 37314061, PMID 31215818, PMID 33750925, PMID 34857525

NIH funding

2008 (1), 2017 (1), 2019 (1)